Omeros (OMER) Given a $30.00 Price Target by HC Wainwright Analysts

Omeros (NASDAQ:OMER) received a $30.00 target price from analysts at HC Wainwright in a report released on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 74.62% from the stock’s previous close.

Other analysts have also issued reports about the company. Maxim Group set a $24.00 target price on Omeros and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research lowered Omeros from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Cowen lowered Omeros from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 2nd. Finally, Wedbush reiterated an “outperform” rating and issued a $47.00 price objective on shares of Omeros in a research report on Tuesday, November 28th. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $34.14.

Shares of Omeros (NASDAQ:OMER) opened at $17.18 on Tuesday. Omeros has a 12 month low of $8.71 and a 12 month high of $27.09. The firm has a market capitalization of $801.66, a price-to-earnings ratio of -13.42 and a beta of 3.56. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.18. The business had revenue of $21.66 million during the quarter, compared to analyst estimates of $17.82 million. During the same quarter last year, the business posted ($0.34) earnings per share. The business’s quarterly revenue was up 91.9% compared to the same quarter last year. sell-side analysts predict that Omeros will post -0.98 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of OMER. Ingalls & Snyder LLC lifted its holdings in shares of Omeros by 3.4% during the 4th quarter. Ingalls & Snyder LLC now owns 5,335,239 shares of the biopharmaceutical company’s stock valued at $103,664,000 after purchasing an additional 174,204 shares in the last quarter. Fox Run Management L.L.C. bought a new position in shares of Omeros during the 4th quarter valued at about $504,000. Mesirow Financial Investment Management Inc. lifted its holdings in shares of Omeros by 35.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 18,808 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 4,940 shares in the last quarter. AMP Capital Investors Ltd bought a new position in shares of Omeros during the 3rd quarter valued at about $279,000. Finally, Stifel Financial Corp lifted its holdings in shares of Omeros by 10.7% during the 3rd quarter. Stifel Financial Corp now owns 394,428 shares of the biopharmaceutical company’s stock valued at $8,522,000 after purchasing an additional 38,268 shares in the last quarter. Hedge funds and other institutional investors own 49.85% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/23/omeros-omer-given-a-30-00-price-target-by-hc-wainwright-analysts-2.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply